Trial Profile
A phase I/Ib, first in human, dose-escalation study of ABTL0812 in patients with advanced solid tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs ABTL 0812 (Primary)
- Indications Adenocarcinoma; Bladder cancer; Bronchial cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Solid tumours; Uterine cancer
- Focus Adverse reactions; First in man
- Sponsors Ability Pharmaceuticals
- 12 Feb 2021 Results published in the European Journal of Cancer
- 07 Nov 2018 Results published in the Ability Pharmaceuticals Media Release
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress